| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.23 | 2e-10 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.21 | 3e-10 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.19 | 1e-07 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-06 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.15 | 2e-06 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.15 | 5e-06 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.41 | 5e-05 |